Robert A. Drakas
Direktor/Vorstandsmitglied bei ShangPharma Innovation, Inc.
Profil
Robert A.
Drakas is currently the Executive Director of ShangPharma Investment Group at Shangpharma Corp., the Director at Azkarra Therapeutics, Inc., and the President at ShangPharma Innovation, Inc. He is also a Board Member at Blue Oak Pharmaceuticals, Inc. Previously, he held positions as the Senior Director of Business Development at Shanghai ChemPartner Co., Ltd.
and as the Vice President at Merck & Co., Inc. Drakas obtained a doctorate degree from Thomas Jefferson University, a graduate degree from Drexel University, and an undergraduate degree from the University of Scranton.
Aktive Positionen von Robert A. Drakas
| Unternehmen | Position | Beginn |
|---|---|---|
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Direktor/Vorstandsmitglied | 01.06.2020 |
Azkarra Therapeutics, Inc.
 Azkarra Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Azkarra Therapeutics, Inc. is a medical research and development company that specializes in providing oncology therapies based on DNA damage response. The company is based in South San Francisco, CA. Mohamad Tabrizi has been the CEO of the company since 2019. | Direktor/Vorstandsmitglied | 01.02.2021 |
Blue Oak Pharmaceuticals, Inc.
 Blue Oak Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Blue Oak Pharmaceuticals, Inc. is a therapeutics developer for brain disorders. Its research is in finding the next generation of drugs for the brain disorders to help patients by creating new medicines, transform the CNS drug discovery paradigm, and achieve rapid clinical neurobiology measures and translational biomarkers. The company was founded by Thomas H. Large and Kerry L. Spear in 2016 and is headquartered in Concord, MA. | Direktor/Vorstandsmitglied | 01.02.2020 |
Shangpharma Corp.
 Shangpharma Corp. Pharmaceuticals: MajorHealth Technology Shangpharma Corp. provides pharmaceutical and biotechnology research outsourcing services. It offers various integrated services across the drug discovery and development process to international and chinese pharmaceutical and biotechnology companies, and academic and research institutions. The company was founded by Michael Xin Hui and Wenjuan Xiao in 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01.04.2016 |
Ehemalige bekannte Positionen von Robert A. Drakas
| Unternehmen | Position | Ende |
|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Shanghai ChemPartner Co., Ltd.
 Shanghai ChemPartner Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai ChemPartner Co., Ltd. operates as a contract research organization. It provides chemistry, biology, pharmacology, DMPK, process R&D, pre-formulation, and analytical development services to global pharmaceutical and biotech companies. The company was founded in 2003 and is headquartered in Shanghai, China. | Corporate Officer/Principal | - |
Ausbildung von Robert A. Drakas
| Thomas Jefferson University | Doctorate Degree |
| Drexel University | Graduate Degree |
| University of Scranton | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Shanghai ChemPartner Co., Ltd.
Shanghai ChemPartner Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai ChemPartner Co., Ltd. operates as a contract research organization. It provides chemistry, biology, pharmacology, DMPK, process R&D, pre-formulation, and analytical development services to global pharmaceutical and biotech companies. The company was founded in 2003 and is headquartered in Shanghai, China. | Commercial Services |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Finance |
Azkarra Therapeutics, Inc.
Azkarra Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Azkarra Therapeutics, Inc. is a medical research and development company that specializes in providing oncology therapies based on DNA damage response. The company is based in South San Francisco, CA. Mohamad Tabrizi has been the CEO of the company since 2019. | Commercial Services |
Blue Oak Pharmaceuticals, Inc.
Blue Oak Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Blue Oak Pharmaceuticals, Inc. is a therapeutics developer for brain disorders. Its research is in finding the next generation of drugs for the brain disorders to help patients by creating new medicines, transform the CNS drug discovery paradigm, and achieve rapid clinical neurobiology measures and translational biomarkers. The company was founded by Thomas H. Large and Kerry L. Spear in 2016 and is headquartered in Concord, MA. | Health Technology |
Shangpharma Corp.
Shangpharma Corp. Pharmaceuticals: MajorHealth Technology Shangpharma Corp. provides pharmaceutical and biotechnology research outsourcing services. It offers various integrated services across the drug discovery and development process to international and chinese pharmaceutical and biotechnology companies, and academic and research institutions. The company was founded by Michael Xin Hui and Wenjuan Xiao in 2002 and is headquartered in Shanghai, China. | Health Technology |
